Cargando…
Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
The management of gastroesophageal reflux disease (GERD) has been revolutionized with the development of proton pump inhibitors (PPIs). Unfortunately, due to the inherent pharmacokinetic and pharmacodynamic profiles of conventional PPIs, many patients continue to suffer from symptoms related to GERD...
Autores principales: | Frye, Jeanetta W, Peura, David A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634831/ https://www.ncbi.nlm.nih.gov/pubmed/26586949 http://dx.doi.org/10.2147/TCRM.S66680 |
Ejemplares similares
-
Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014) -
Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole
por: Wu, Justin C Y, et al.
Publicado: (2020) -
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
por: Mermelstein, Joseph, et al.
Publicado: (2016) -
Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis
por: Wittbrodt, Eric T, et al.
Publicado: (2009) -
Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
por: Goh, Khean Lee, et al.
Publicado: (2016)